requesting information regarding Rebate and QIPP prescribing schemes in NHS Canterbury and Coastal Clinical Commissioning Group
|
|
|
- Alan Powell
- 5 years ago
- Views:
Transcription
1 July 2015 Our Ref: FOI.15.CAN0059 requesting information regarding Rebate and QIPP prescribing schemes in NHS Canterbury and Coastal Clinical Commissioning Group Could you please provide me with the details of any prescribing rebate schemes and QIPP prescribing schemes active within your CCG during the financial year 2014/15? Please answer the questions below: 1. Primary Care Prescribing Rebate Schemes Name of Scheme Drug(s) covered Nutricia enteral and sip feeds Pradaxa Rivaroxaban (Xarelto) GlucoRx diabetes monitoring products Insuman, Apidra, Lantus Degarelix Prostap DCS Companies involved in the scheme Nutricia Boehringer-Ingelheim Bayer GlucoRx Sanofi Ferring Takeda 2. What was the total income for the CCG from rebates during 2014/15? I can confirm the total income for NHS Canterbury and Coastal Clinical Commissioning Group from rebates during the financial period is 257, QIPP Prescribing Schemes ECLIPSE LIVE alerts Name of Scheme Drug(s) covered Not relevant for quality measures
2 Uncomplicated UTI audit 8 consultations per prescriber standard 70% # Sore throat audit 8 consultations per prescriber standard 70% # Quinolone audit 6 consultations per prescriber standard 70% # PRIMIS audit tool Preferred tools cover COPD Drug(s) Covered by Project BNF Cost effective use of Proton Pump Inhibitors (May BNF Cost-effective use of Omeprazole (May BNF Cost effective mesalazine (March BNF Macrogol 3350-Cost effective options-cosmocol (first choice) or Laxido (March BNF Angiotensin-II receptor antagonist optimisation BNF Doxazosin Optimisation BNF Perindopril arginine (Coversyl Arginine and Coversyl Arginine DROP list (DRugs of LOw Priority) BNF Glyceryl Trinitrate sprays (June BNF Isosorbide Mononitrate MR 60mg optimisation BNF Amlodipine cost effective prescribing BNF Clopidogrel / Dipyridamole Optimisation BNF Clopidogrel optimisation (May BNF Ezetimibe Optimisation BNF Omega-3 fatty acid compounds BNF Rosuvastatin BNF Statin Optimisation BNF Salbutamol inhalers- cost effective preparations BNF LAMA Optimisation BNF Cost effective budesonide/formoterol inhalers (High strength) (June BNF Cost effective budesonide/formoterol inhalers (June
3 BNF ICS/LABA Project 1 Options for pmdi preparations used at Step 3 of the BTS guidance (Updated June BNF ICS/LABA Project 2 Options for DRY POWDER preparations used at Step 3 of the BTS guidance (Updated June BNF ICS/LABA Project 3 Budesonide/formoterol- cost effective options for this preparation and safety considerations (Updated June BNF ICS/LABA Project 4 Cost effective options for preparations containing fluticasone (Updated June BNF Seretide 250/25 Evohaler monitoring BNF Montelukast cost effective prescribing (May BNF Antihistamines DROP topic (DRugs of LOw Priority) BNF Decongestants, aromatic inhalations, cough mixtures. DROP list (DRugs of LOw Priority) BNF Antipsychotics optimisation-olanzapine BNF Antipsychotics optimisation-risperidone BNF Amisulpride optimisation BNF Aripiprazole dose optimisation BNF Quetiapine immediate release vs Modified release (June BNF use of branded generics for Quetiapine 150mg XL preparations. (June BNF use of branded generics for Quetiapine 200mg XL preparations (June BNF use of branded generics for Quetiapine 300mg XL preparations (June BNF use of branded generics for Quetiapine 400mg XL preparations (June BNF use of branded generics for Quetiapine 50mg XL preparations (June BNF use of generic quetiapine 100mg BNF use of generic quetiapine 150mg BNF use of generic quetiapine 200mg BNF use of generic quetiapine 25mg BNF use of generic quetiapine 300mg BNF Escitalopram cost effective prescribing (May BNF Sertraline cost effective prescribing (May BNF Venlafaxine optimisation
4 BNF Modafinil cost effective prescribing BNF Orlistat BNF Co-codamol 30/500mg cost effective preparations BNF Co-codamol 30/500mg cost effective preparations-soluble preparations BNF Analgesia for minor/common ailments. DROP list (DRugs of LOw Priority) [Some overlap with Paracetamol project] BNF Co-proxamol DROP list (DRugs of LOw Priority) BNF Fentanyl lozenges DROP list (DRugs of LOw Priority) BNF Fentanyl optimisation 12 micrograms BNF Fentanyl optimisation 25 micrograms BNF Fentanyl optimisation 50 micrograms BNF Fentanyl optimisation 75 micrograms BNF Oxycodone immediate release preparation-optimisation BNF Oxycodone Modified Release Preparations-Optimisation 10mg BNF Oxycodone Modified Release Preparations-Optimisation 20mg BNF Oxycodone Modified Release Preparations-Optimisation 40mg BNF Oxycodone Modified Release Preparations-Optimisation 5mg BNF Oxycodone Modified Release Preparations-Optimisation 80mg BNF Oxycodone/ Naloxone (Targinact ) DROP list (DRugs of LOw Priority) BNF Tramacet DROP list (DRugs of LOw Priority) BNF Tramadol Immediate release optimisation 50mg BNF Tramadol Modified release optimisation 100mg BNF Tramadol Modified release optimisation 150mg BNF Tramadol Modified release optimisation 200mg BNF Tramadol Modified release optimisation 50mg BNF Triptans-Cost-effective use BNF Pregabalin 25mg BNF Pramipexole cost effective prescribing (May BNF Buprenorphine sublingual cost effective prescribing (May BNF Galantamine optimisation BNF Minocycline. DROP list (DRugs of LOw Priority) BNF Intermediate and long acting Insulins- Use NPH insulin first line BNF Pen needles (Revised measure Oct 2014)
5 BNF Gliclazide MR 30mg. DROP list (DRugs of LOw Priority) BNF Blood Glucose Test strips BNF Lancets BNF Prednisolone 5mg Optimisation BNF Desmopressin cost effective prescribing of nasal spray (May BNF Desmopressin cost effective prescribing of tablets (May BNF Bisphosphonate optimisation (May BNF COC (Project 1) Gedarel 20/150 in place of Mercilon BNF COC (Project 2) Millinette 20/75 in place of Femodette or Sunya 20/75 BNF COC (Project 3) Gedarel 30/150 in place of Marvelon BNF COC (Project 4) Lucette in place of Yasmin BNF COC (Project 5) Millinette 30/75 in place of Femodene or Katya 30/75 BNF COC (Project 6) Rigevidon in place of Microgynon 30, Ovranette or Levest BNF COC (Project 7) TriRegol in place of Logynon BNF POP Cerelle in place of Ceravette BNF Tolterodine MR to Neditol XL BNF Drugs for erectile dysfunction- generic sildenafil vs high cost alternatives (Amended Dec 2014) BNF Sildenafil cost effective prescribing (May BNF Anastrazole Optimisation (May BNF Gonadorelin analogues (May (Preparations for one month duration of treatment) BNF Gonadorelin analogues (May (Preparations for three months/12 weeks duration of treatment) BNF Appendix Nutritional supplements-ensure Cans BNF Appendix Nutritional supplements-aymes Shake is more cost effective than Complan Shake (March BNF A Colief DROP list (DRugs of LOw Priority) BNF A VSL#3 DROP list (DRugs of LOw Priority) BNF Vitamins and minerals-unlicensed BNF Calcium and Vitamin D -DROP list (DRugs of LOw Priority) BNF Ibuprofen and naproxen as % of all NSAIDs BNF Glucosamine
6 BNF Ibruprofen gel 10% switch to branded generic BNF Ibuprofen gel 5% to branded generic BNF Movelat to Algesal BNF Dorzolamide (and combination products) optimisation BNF Latanoprost (and combination products) optimisation BNF Mometasone nasal spray cost effective prescribing (May BNF Nystatin suspension optimisation BNF Cost effective emollients - ZeroAQS (Aqueous Cream Alternative) BNF Cost effective emollients - Zerobase (Diprobase Cream Alternative) BNF Cost effective emollients - Zerocream (E45 Cream Alternative) BNF Cost effective emollients - Zeroderm (Epaderm alternative) BNF Cost effective emollients - Zerodouble Gel (Doublebase Gel Alternative) BNF Cost effective emollients - Zeroguent Cream (Unguentum M Cream Alternative) BNF Emollient bath and shower - cost effective preparations BNF Fflornithine (Vaniqa) DROP list-drug of Low Priority BNF Topical Antifungals DROP list (DRugs of LOw Priority) BNF Cost effective Lymecycline Preparation BNF Vaccinations for Hepatitis B and Meningitis ACWY (June BNF Travel vaccines (June
requesting information regarding Referral target schemes for GPs in NHS Ashford Clinical Commissioning Group
August 2015 Our Ref: FOI.15.ASH0102 requesting information regarding Referral target schemes for GPs in NHS Ashford Clinical Commissioning Group a) Does the CCG currently operate any schemes for GPs which
DT Description Price Category Price change
Tariff T Watch October 2014 Readers are no doubt aware of this quarter's bad news for primary care prescribing allocations: NHS England has d the remuneration mechanism for community pharmacies gaining
DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M %
June 2016 On 13th May, the DH announced that there would be reductions to Category M prices from June until September. http://psnc.org.uk/our-news/contractor-notice-category-m-price-reduction/ This has
While there is around a 3% increase shown in costs for Category M lines, I think this is due to the inclusion of more lines in Category M.
April 2018 The usual quarterly of Category M prices Another set of similar comments as I made in January: significant increases in many lines which have been subject to price concessions but even more
Items which should not routinely be prescribed in primary care: Summary of PCN statements PCN to PCN
Items which should not routinely be prescribed in primary care: Summary of PCN statements PCN 302-2018 to PCN 318-2018 In November 2017, NHS England issued final guidance in relation to items which should
requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group
requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14
DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 702 M %
December 16 No Category M changes so the reductions imposed in May which were only supposed to last until September continue As in November, most changes are Category A lines with a few Category C. Significant
DT Description Price Category Price change Percentage
June 2017 A slight inflationary pressure in most CCGs from mainly Category A increases. Significant price increases: Most of low concern although those involving the less frequently used tamoxifen strengths
Found in practice. Joint Formulary. Joint Formulary. Embedded into practice. Embedded into practice. As above. As above.
IPSWICH HOSPITAL ADULT THERAPEUTIC SUBSTITUTION REGISTER FOR PHARMACISTS What s New? New Substitutions Added exclusion criteria of Recommended by psychiatry to escitalopram switch Enoxaparin 40mg to 20mg
NHFT Contraceptives Formulary January 2017
NHFT Contraceptives Formulary January 201 Contents Contraceptives... 2 Combined hormonal contraceptives... 2 Progestogen-only contraceptives... 2 Contraceptve devices... 3 Emergency Contraception... 3
Wolverhampton CCG Medicines Optimisation Work plan 2017/18
Wolverhampton CCG Medicines Optimisation Work plan 2017/18 Wolverhampton Clinical Commissioning Group 1 Contents page Overall Outcomes 3 Patient Safety 3 Medicines Commissioning 4 QIPP 5 Areas of cost
FREEDOM OF INFORMATION DECISION NOTICE. FOI Reference Number: 870
Scarsdale Nightingale Close Newbold Chesterfield S41 7PF Tel.: 01246 514048 Date: 5 June 2018 FREEDOM OF INFORMATION DECISION NOTICE Dear Sir / Madam, FOI Reference Number: 870 I refer to your email of
Swindon PCT/CCG - Cost based ASTRO-PU variance to the England average prescribing spend by month
Appendix x Swindon CCG Primary Care Prescribing Costs and Patient Outcomes Variance to the England average 105.00% Swindon PCT/CCG - Cost based ASTRO-PU variance to the England average prescribing spend
Wirral CCG Prescribing Incentive Scheme Summary
Wirral CCG Prescribing Incentive Scheme 13-14 Summary Wirral wide scheme to run from July 2013 February 2014. Incentive monies available up to 1.50 per head of practice population (based on April 2013
PRESCRIPTION CLERK TRAINING EVENT SAFE, EFFECTIVE AND COST-EFFECTIVE PRESCRIBING PRESCRIBING INCENTIVE SCHEME
PRESCRIPTION CLERK TRAINING EVENT SAFE, EFFECTIVE AND COST-EFFECTIVE PRESCRIBING PRESCRIBING INCENTIVE SCHEME ACCESSING THE MEDICINES MANAGEMENT WEBSITE This we take you to a range of documents, policies
CONSULATION ON ITEMS WHICH SHOULD NOT BE ROUTINELY PRESCRIBED IN PRIMARY CARE FREQUENTLY ASKED QUESTIONS
CONSULATION ON ITEMS WHICH SHOULD NOT BE ROUTINELY PRESCRIBED IN PRIMARY CARE FREQUENTLY ASKED QUESTIONS Consultation content: 18 products Patient experience Savings Working group Over-the-counter medicines
Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).
Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex CCG Guidelines for the
Medicines Management Programme Update
Medicines Management Programme Update Sarah Clarke Chief II Pharmacist and Programme Manager Medicines Management Programme (MMP) www.hse.ie/yourmedicines Millions ( ) The Medicines Management Programme
Berkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
PORTFOLIO Q June 2014 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/5
Abiraterone Tablet 250 mg Q4 2015 Acetylsalicylic Acid Tablet GR 100 mg Available Aciclovir Cream 5% - 2 Grs Q4 2014 Alendronic Acid Tablet 70 mg Available Amisulpride Tablet 50 ; 100 ; 200 ; 400 mg Available
SW Locality PBC Consortium Notes re Prescribing Data
SW Locality PBC Consortium Notes re Prescribing Data Enclosed data is for SW Locality PBC Consortium practices from current 12 months as at Mar 07 Top 50 by cost identified Areas that could achieve quick
Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015
Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A 294.3 for use in Northern Ireland) Sep 2015 BNF 1.3.5 Proton pump inhibitors Lansoprazole orodispersible
November 2018 Review date: November 2020
November 2018 Review date: November 2020 Executive Summary 3 Introduction 4 Background 4 Scope 5 Resources to implement this policy 6 Policy review 6 Table of items with formulary indication 7 Co-proxamol
Medicines Formulary BNF Section 4 Central Nervous System
Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam
Hormonal contraception: NHS Tayside Formulary, pharmacological content and other characteristics
Hormonal contraception: NHS Tayside Formulary, pharmacological content and other characteristics Advice from the Tayside Sexual & Reproductive Health Service (TSRHS) (Last update: 10/2017) Combined hormonal
Medicines Optimisation Annual Report Dr Emma Harris and Neil Hardy on behalf of the Medicines Management Team June 2016
Medicines Optimisation Annual Report 2015-2016 Dr Emma Harris and Neil Hardy on behalf of the Medicines Management Team June 2016 1 Clinical Objectives Improve the effective use of medicines Maximise health
Items which should not routinely be prescribed in primary care: A Consultation on guidance for CCGs
Items which should not routinely be prescribed in primary care: A Consultation on guidance for CCGs Items which should not routinely be prescribed in primary care: A Consultation on guidance for CCGs Version
Chapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices
Chapter 2 - Cardiovascular System Primary Care Prescribing Formulary - Preferred Drug Choices Drug group Drug choice Comments/notes Cardiac glycosides Thiazide diuretics Loop diuretics Aldosterone antagonist
Step Therapy Medications
Step Therapy Medications Step Therapy Group APTIOM Step-2: APTIOM 200 MG TABLET or APTIOM 400 MG TABLET or APTIOM 600 MG TABLET or APTIOM 800 MG TABLET Step 1 Drug(s): Oxcarbazepine immediate-release,
Agenda Item: 16 NHS Norwich CCG Governing Body Tuesday 25 th July 2017
Agenda Item: 16 NHS Norwich CCG Governing Body Tuesday 25 th July 2017 Subject: Presented By: Submitted To: Purpose of Paper: Self-care for Self-Limiting Conditions Policy Karen Watts, Director of Quality
NI Formulary: Chapter 4 Central Nervous system
Hypnotics Anxiolytics Acute state Non drug treatment Temazepam tablets 10mg, 20mg; oral solution 10mg/5ml or Zolpidem tablets 5mg, 10mg or Zopiclone 3.75mg, 7.5mg Non drug treatment Diazepam tablets 2mg,
Bradford Contraception and Sexual Health Services FORMULARY
Bradford Contraception and Sexual Health Services FORMULARY Medication Stock Item Strength Form Pack Size Indication Acetone Liquid 50ml For lab use Aciclovir TTO (PGD) 400mg Tablets 15 Herpes Treatment
PORTFOLIO Q October 2015 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/6
Abiraterone Tablet 250 mg Q4 2016 Acetylsalicylic Acid Tablet GR 100 mg Available Aciclovir Cream 5% - 2 Grs Available Alendronic Acid Tablet 70 mg Available Amikacin Solution for injection 50 mg/ml; 125mg/ml;
List of changes in Out-Patients Formulary
List of changes in Out-Patients Formulary Change in prescriber criteria Alpha Tocopheryl (Vitamin E) suspension 100mg/mL, tablets 50-150mg, tablets 670mg Atorvastatin tablets Bezafibrate tablets 400mg
QIPP Prescribing Comparators: Description and Specification
Prescribing s: Description and Specification This document details the descriptions and specifications for the prescribing comparators. They should be read in conjunction with the National Prescribing
Chapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
Promotion of Self Care Briefing Document
RCCG/GB/17/035 Promotion of Self Care Briefing Document 1. Introduction The proposal aims to promote self-care through the purchasing of medications and products from local pharmacies for the treatment
NICE update. Paul Chrisp, Programme Director, Medicines and Prescribing Centre
NICE update Paul Chrisp, Programme Director, Medicines and Prescribing Centre Outline NICE offers a comprehensive suite of guidance, advice and support for delivering quality, safety and efficiency in
Treating the symptoms of kidney failure
Treating the symptoms of kidney failure Information for patients, relatives and carers Renal Department The York Hospital and Scarborough Hospital Tel: 01904 725370 For more information, please contact:
Medicines availability short-term supply issues Last updated 01/05/18
Short-term supply issues This resource includes availability information on medicines that are reported to have supply issues, with next expected availability within the next three months. This list is
Calgary Long Term Care Formulary. Pharmacy & Therapeutics. February 2015
Calgary Long Term Care Formulary Pharmacy & Therapeutics February 2015 Highlights http://www.albertahealthservices.ca/4070.aspx 1 Contents February 2016... 3 Added Product(s)... 3 Not Listed, Delisted
Reviewing Medicines in at risk patients care homes
Reviewing Medicines in at risk patients care homes Clinical Medication Reviews by Pharmacists in Collaboration with GP Surgeries across Brighton and Hove CCG Liz Butterfield FRPharmS 19th April 2016 NICE:
GENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY
GENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY First issued by/date Issue Version Purpose of Issue/Description of Change Planned Review Date August 2018 1.0 Promoting generic prescribing whenever
CHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
Part IX (a) List Of Preparations Approved By The Department That May Be Prescribed On Form HS21D By Dentists
Part IX (a) List Of Preparations Approved By The Department That May Be Prescribed On Form HS21D By Dentists Aciclovir Cream BP Aciclovir Oral Suspension BP 200mg/5ml Aciclovir Tablets BP 200mg, 800mg
Prescribing in the Elderly. Dr Alison Macrae and Dr Debbie Vest GPST2 Drs in Psychiatry
Prescribing in the Elderly Dr Alison Macrae and Dr Debbie Vest GPST2 Drs in Psychiatry 24 th September 2014 Objectives Understand the significance of polypharmacy in the elderly Become familiar with the
MeReC Bulletin. MeReC Publications. Vol.22 No.03 January 2012
MeReC Bulletin Vol.22 No.03 January 2012 MeReC Publications Implementing key therapeutic topics: 1 NSAIDs; antibiotics; and inhaled corticosteroids in asthma The QIPP agenda aims to ensure that value for
Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir
Acyclovir Ointment Mercy Care Plan acyclovir ointment 5 % external Requires use of oral Acyclovir 1 Adcirca ADCIRCA TABLET 20 MG ORAL Requires use of Sildenafil 2 Albenza ALBENZA TABLET 200 MG ORAL Requires
Alprazolam 0.25mg, 0.5mg, 1mg tablets
Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service
AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details
AMANTADINE ER OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE OSMOLEX ER 258 MG TABLET, PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
NHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.21.07.2017/05 Title: Items which should not routinely be prescribed in primary care Lead Director: Professor Sir Bruce Keogh, Medical Director Paul Baumann, Chief Financial
Short-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
Medicines which should not be regularly prescribed in primary care. Consultation. Information booklet
Medicines which should not be regularly prescribed in primary care Consultation Information booklet About this document When we say primary care, we mean the medical services that people go to first. These
Policy for Conditions for which over the counter items should not routinely be prescribed in primary care.
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
Optimising Insulin Pen Needles
Optimising Insulin Pen Needles Following a review of insulin pen needles NHS Telford and Wrekin CCG now recommends the use of GlucoRx FinePoint Pen Needles. GlucoRx FinePoint Pen Needles are a high quality
Appendix 1 Consultation Document and Survey
Appendix 1 Consultation Document and Survey Proposals to stop prescribing medicines for minor conditions NHS Blackburn with Darwen Clinical Commissioning Group continuously reviews the services it commissions
Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria
ALBENDAZOLE Mercy Care ALBENZA TABLET 200 MG ORAL Refer to PA Guideline for approval criteria 1 BRIMONIDINE-TIMOLOL COMBIGAN SOLUTION 0.2-0.5 % OPHTHALMIC Requires use of separate ingredients for at least
ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria
ANTIDEPRESSANTS Trintellix 10 mg tablet Trintellix 20 mg tablet Trintellix 5 mg tablet Viibryd 10 mg (7)-20 mg (23) tablets in a dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet
STEP THERAPY PROGRAM
STEP THERAPY PROGRAM Step Therapy Program Certain prescription drugs call for a more detailed assessment to help ensure that they represent reasonable treatment. For these drugs, Great-West s Special Authorization
Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria
Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time
CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.
ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE
Identifying High Greenhouse Gas Intensity Prescription Items for NHS in England. Final Report. February 2014
Identifying High Greenhouse Gas Intensity Prescription Items for NHS in England Final Report February 2014 Delivering sustainable solutions in a more competitive world Sustainable Development Unit Identifying
ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY
South Country Health Alliance 2017 Step Therapy Formulary ID: 17431 Last Updated: 10/20/2017 Effective Date: 11-01-2017 ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY BENICAR 20 MG BENICAR 40 MG BENICAR 5
Step Therapy Requirements. Effective: 1/1/2019
Effective: 1/1/2019 Updated 1/2019 AMANTADINE ER Sharp Health Plan (HMO) OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED RELEASE PRIOR CLAIM FOR AMANTADINE
Changing the way we prescribe in Calderdale. Consultation document
Changing the way we prescribe in Calderdale Consultation document Who are we? Clinical commissioning groups (CCGs) are responsible for planning and buying (commissioning) healthcare. We are made up of
Simply Step Therapy Document September 2018 Y0114_18_33074_I_009
2018 2018 Simply Step Therapy Document September 2018 Aptiom APTIOM 200 MG TABLET APTIOM 400 MG TABLET Y0114_18_33074_I_009 APTIOM 600 MG TABLET APTIOM 800 MG TABLET Criteria If the patient has tried a
Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
1 e f forte.uk.com t Nov 2016
t 0370 241 8717 e info@forte.uk.com f 01622 790 754 forte.uk.com Nov 2016 During this year s DDA 2016 Annual Conference, pharmacy minister David Mowat announced details of the funding cuts to affect community
AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details
AMANTADINE ER OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE OSMOLEX ER 258 MG TABLET, PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
Step Therapy Requirements. Effective: 05/01/2018
Step Therapy Requirements Effective: 05/01/2018 ANTIDEPRESSANTS TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK VIIBRYD 10 MG
2017 Step Therapy Criteria
FRESENIUS TOTAL HEALTH 2017 Step Therapy Updated 07/01/2017. For more recent information or other questions, please contact Fresenius Total Health Customer Service at 1-855-598-6774 / TTY 1-844-209-9094.
Volume 4; Number 17 November 2010
Volume 4; Number 17 November 2010 USE OF UNLICENSED PHARMACEUTICAL SPECIALS What are pharmaceutical specials? A pharmaceutical special as defined by law is a medicine made to satisfy an individual patient
3. Respiratory System
1 3. Respiratory System Also see Appendix 3A Guidance on Management of Also see Appendix 3B Preferred Inhaler Devices for Adults Also see Appendix 3C Preferred Inhaler Devices for Adolescents (12-18 years)
Volume 11; Number 4 March 2017 LINCOLNSHIRE PACEF DROP LIST: DRUGS TO REVIEW FOR OPTIMISED PRESCRIBING
Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust Volume 11;
2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)
2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) In some cases, UCare requires you to first try certain drugs to
7: Obstetrics, gynaecology, and urinary tract disorders
Original Date of issue: 31/12/2005 Last eviewed: 11/11/2011 Version:4 Page 1 of 6 7: Obstetrics, gynaecology, and urinary tract disorders 7.1 Drugs used in obstetrics 7.1.1 Prostaglandins and oxytocics
Step Therapy Requirements. Effective: 11/01/2018
Effective: 11/01/2018 Updated 10/2018 ANTIDEPRESSANTS Sharp Health Plan (HMO) TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK
Drug Regimen Optimization
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
ALLERGIC CONJUNCTIVITIS AGENTS
2018 5 Tier Standard- Keystone First VIP Choice Document: 2018 Step Therapy Formulary ID: 18390 Last Updated: 04/2018 Effective Date: 05-01-2018 ALLERGIC CONJUNCTIVITIS AGENTS epinastine 0.05 % eye drops
Calgary Long Term Care Formulary
Page 1 of 10 Calgary Long Term Care Formulary Pharmacy & Therapeutics November 2018 Highlights https://www.albertahealthservices.ca/info/page4071.aspx Page 2 of 10 Contents November 2018... 3 Formulary
July Formulary Policy
Formulary Policy July 2017 Responsible Committee: Quality Committee Date Effective: July 2017 Author: Rahinatu Amadu Supersedes: July 2016 Next Review Due: July 2018 Formulary Policy 2016-2018 1. INTRODUCTION
Step Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet
Chapter 4 ~ Central nervous system
Chapter 4 ~ Central Nervous System: Special Section 1 of 5 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics LOPRAZOLAM Tablet 1mg LORMETAZEPAM Tablet 500microgram PROMETHAZINE
VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019
VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 04/01/2019 Updated 03/2019 AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS
GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS Bristol Palliative Care Collaborative Contact Numbers: Hospital Specialist Palliative Care Teams: North Bristol 0117 4146392 UH Bristol 0117
Summary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
Kern Pharma Portfolio 2014
Kern Pharma Portfolio 2014 DOSSIERS DEVELOPED DURING 2013-2014 ARIPIPRAZOL (ODT) 10mg, 15mg tablets CHONDROITIN SULPHATE 400mg capsules ( well established use ) DEXKETOPROFEN TROMETAMOL 25mg, tablets DULOXETIN
ANTIEMETICS STEP. Step Therapy Requirements Effective April 1, 2019
Step Therapy Requirements Effective April 1, 2019 ANTIEMETICS STEP Sancuso 3.1 mg/24 hour transdermal patch Zuplenz 4 mg oral soluble film Zuplenz 8 mg oral soluble film COVERAGE OF CERTAIN BRAND NAME
Prescribing Dilemmas. Sue Mulvenna Head of Pharmacy and CD Accountable Officer South Region SW 19 th May
Prescribing Dilemmas Sue Mulvenna Head of Pharmacy and CD Accountable Officer South Region SW 19 th May 2016 The four principles of medicines optimisation Aim to understand the patient s experience Evidence
Self-care aware When should you prescribe?
Self-care aware When should you prescribe? Over-the-counter medicines can only be sold within their licensed indications and in limited quantities in some cases. Below are some examples of instances when
PRESCRIBING INCENTIVE SCHEME 2018/19
PRESCRIBING INCENTIVE SCHEME 2018/19 Summary Harrogate and Rural District CCG is continuing to offer a prescribing incentive scheme to all its member NHS GP practices as encouragement and reward to improve
Volume 8; Number 1 January 2014
Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire
Hertfordshire and West Essex Sustainability and Transformation Partnership. Welcome
Welcome What is an STP? Herts Valleys CCG, East and North Hertfordshire CCG and West Essex CCG working together with county and district councils The challenges we face Prioritising health services in
Over-the-counter medicines. Patient Information: Medicines. NHS Logo here. Working together for better patient information
Patient Information: Medicines NHS Logo here Over-the-counter medicines Health & care information you can trust The Information Standard Certified Member Working together for better patient information
General Practice Summary
Page 1 of 6 General Practice Summary Summary Care Record Yasmin CHIDAMBER DoB 23-Sep-1939 Female NHS 946 376 4607 GP Practice A20063 Address 10 HAUXTON ROAD, LITTLE SHELFORD, CAMBRIDGE, UNITED KINGDOM,